The Evaluation of blood pressure treatment stratified according to Central Aortic Systolic Pressure (CASP) in Young Hypertensive Patients - The TREAT CASP study
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
High blood pressure (BP) is a leading cause of heart disease and strokes and the commonest chronic condition treated in primary care. In the UK, ~25% of all adults and 50% aged over 65yrs have high BP. NICE guidance recommends treatment when BP exceeds 160/100mmHg (called stage II hypertension). NICE also recommends treatment of lower pressures (140-159/90-99mmHg, i.e. stage I hypertension) in those with evidence of damage due to BP, those with diabetes and/or cardiovascular disease (CVD) or those calculated to be at higher risk. However, there is uncertainty what to do about treatment of younger people (aged 40yrs and under) with stage I hypertension because; i) younger people have rarely been included in clinical trials, ii) are unlikely to have developed CVD and iii) risk calculators do not apply to this younger age group. NICE has identified this group of over 1 million younger people as a key priority for research to better identify who would benefit from treatment. BP is routinely measured with a cuff wrapped around the arm and the assumption is made that pressure measured in the arm accurately reflects the pressure in the artery (aorta) close to the heart and the vital organs. We have developed a simple, non-invasive method to measure pressure in the aorta, next to the heart. This pressure is termed "central aortic systolic pressure" or CASP. Importantly, we have shown that pressure in the arm may not be an accurate measure of CASP, especially in younger people. Moreover, CASP is a better predictor of stress on the heart and may better predict stroke and CVD compared to BP measured in the arm. Our study will take place at the UCL vascular physiology unit and will recruit young men (aged 18-40 years) with stage I hypertension. We hypothesise that men with a low CASP (despite a high BP in the arm) actually have a normal BP, with no evidence of strain on the heart and do not need treatment. In contrast, those with a high CASP value will have early evidence of strain on the heart and arteries and will benefit from treatment. We will use MRI to sensitively measure the structure of the heart and the arteries. We will compare in men with high CASP, the effects of treatment for 1 year to lower BP versus no treatment, to see whether lowering CASP improves early heart and artery damage. Our study has no ethical issues as people recruited into the study would not normally receive treatment. We are well placed to conduct this study because of our experience in developing novel ways of measuring CASP, our experience in large clinical trials and in sensitive MRI measurements. The cost of our study is curtailed because of access to our research technology, including our research MRI scanner. Resources requested are to fund staff, clinical tests and consumables. Findings from our study may provide compelling evidence for a better way to stratify younger people with early hypertension who would benefit most from treatment and also avoid long-term treatment of those who would get no benefit.
Technical Summary
Research design: This two-stage study incorporates a stage 1 screening study (n=500) to identify men with HIGH and LOW CASP values who will enter a Stage 2 randomized clinical trial (RCT) using a PROBE design (n=130), or an observational follow up study (n=65). Study population: Men aged 18-40 years with stage 1 hypertension (brachial blood pressure 140-159/90-99mmHg) not currently treated and without cardiovascular disease (CVD) or target organ damage. Exclusions include men with secondary hypertension, target organ damage, diabetes, significant arrhythmia. Planned Interventions: Stage 1 has no intervention. The Stage 2 RCT will compare no treatment (control intervention) versus BP lowering (active treatment) according to NICE treatment guidelines for people aged <55years, with titration to achieve a CASP value of <120mmHg and/or at least a 5mmHg reduction from baseline Proposed Outcome Measures:Primary outcome is the change in left ventricular mass index (LVMI) from baseline to study end (12 months), between treatments. Secondary outcomes are markers of cardiovascular damage measured by MRI including LV mass/volume ratio; CMR myocardial tissue tagging; interstitial fibrosis; aortic distensibility; carotid and aortic wall thickness. Albumin excretion rate and retinal photography comprise other outcomes. Assessment & Follow up: In Stage 1, brachial BP and CASP will be measured by CASPro (n=500) which combines a BP monitor with radial tonometry. At the end of Stage 1, 130 men with HIGH CASP and 65 men with LOW CASP values will undergo measurement of LVMI by MRI. In the RCT and observational follow-up (Stage 2), brachial BP and CASP will be monitored at scheduled, 3 monthly follow-up visits, with more frequent visits during titration for the active treatment group. LVMI and secondary outcomes will be measured by MRI after 12 months follow up for all Stage 2 groups. Proposed sample size: The Stage 2 RCT will compare treatment vs. no treatment in groups of 65 men from the HIGH CASP group. We anticipate a change in LVMI between treatments of 6.6 g/m2 based on published data from 4 treatment studies comprising 7 active treatment arms in 627 individuals, SD 10.9g/m2. Power calculations indicate a sample size of 58 people per treatment are required to show a difference in LVMI with 90% power at p=0.05. Statistical analysis: The primary analysis at the end of the Stage 2 will use a linear regression model to compare the change in LV mass from baseline to study end between treatments. A students” t-test will also be used at the end of Stage 1 to compare values for LV mass index between the HIGH and LOW CASP groups. Projected timetables: 500 men with stage 1 hypertension will be identified and screened in the first 18 months of the study (Stage 1). The expected recruitment rate is similar to that of our previous screening studies. A 1 year RCT and an observational follow-up study (Stage 2) will follow completion of Stage 1.
Organisations
- University College London (Lead Research Organisation)
- Farr Institute of Health Informatics Research (Collaboration)
- University College London (Collaboration)
- Relypsa, Inc. (Collaboration)
- University College Hospital (Collaboration)
- Novartis (Collaboration)
- Medicines and Healthcare Regulatory Agency (Collaboration)
- Royal College of Physicians of London (Collaboration)
- National Institute for Health Research (Collaboration)
- NHS ENGLAND (Collaboration)
- European Society of Cardiology (ESC) (Collaboration)
People |
ORCID iD |
Bryan Williams (Principal Investigator) |
Publications


Agarwal R
(2018)
Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study
in American Journal of Nephrology

Agarwal R
(2020)
Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER - Authors' reply.
in Lancet (London, England)

Agarwal R
(2020)
Spironolactone for resistant hypertension in advanced chronic kidney disease-red, amber or green?
in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Agarwal R
(2021)
Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial.
in Kidney360

Alshehry ZH
(2016)
Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus.
in Circulation

Atkins ER
(2017)
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials.
in Journal of hypertension

Bakris G
(2018)
Hypertension: A Companion to Braunwald's Heart Disease

Banegas J
(2014)
High prevalence of masked uncontrolled hypertension in people with treated hypertension
in European Heart Journal

Banegas Jose R.
(2018)
Ambulatory Blood Pressure and Mortality Reply
in NEW ENGLAND JOURNAL OF MEDICINE
Description | Appointed President of International Society of Hypertension |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | British Heart Foundation Clinical Study Grant - Co-investigator |
Amount | £754,472 (GBP) |
Funding ID | BHF Clinical Study no. CS/17/3/32799 "Biomarkers in urine, anyihypertensive treatment and blood pressure control in hypertensive patients - outreach study" |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2017 |
End | 05/2020 |
Description | British Heart Foundation Special programme Grant |
Amount | £1,000,000 (GBP) |
Funding ID | TIME study - Treatment In the Morning versus Evening (TIME) BHF CS/14/1/30659 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2014 |
End | 06/2019 |
Description | Health Data Research UK - pan-London site - Co-investigator (H. Hemingway - lead applicant) |
Amount | £5,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2023 |
Description | Investigator-led Industrial Research grant award |
Amount | £150,000 (GBP) |
Organisation | Omron Corporation |
Sector | Private |
Country | Japan |
Start | 09/2020 |
End | 09/2022 |
Description | NIH University College London Hospitals Clinical Research Facility - Co-applicant |
Amount | £6,500,000 (GBP) |
Organisation | National Institute for Health Research |
Department | UCLH/UCL Biomedical Research Centre |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2017 |
End | 03/2022 |
Description | NIHR BRC competition 3 - Resdesignation and new funding award to NIHR University College Hospitals Biomedical Research Centre - Director |
Amount | £111,500,000 (GBP) |
Organisation | National Institute for Health Research |
Department | UCLH/UCL Biomedical Research Centre |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2017 |
End | 03/2022 |
Description | Wellcome Trust Strategic Award - Electronic Health Records |
Amount | £50,000 (GBP) |
Organisation | Wellcome Trust |
Department | Wellcome Trust Strategic Award |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2016 |
End | 02/2017 |
Title | Development of new methods to measure central aortic pressure |
Description | developed a novel method to measure aortic pressure from the radial pulse wave. this meted has been commercialised and is now widely used in research. the method has been adopted as a US FDA standard for central aortic pressure measurement |
Type Of Material | Physiological assessment or outcome measure |
Year Produced | 2011 |
Provided To Others? | Yes |
Impact | research grant to my group from NIHR EME/MRC to evaluate its use in better stratification of treatment decisions for young people with hypertension. used by Novartis Pharma in evaluating new drug efficacy in clinical trials |
URL | http://www.healthstats.com/index3.php |
Title | Developing methods to assess aortic function and flow using MRI |
Description | Using MRI physics to model aortic haemodynamics in relation to the evaluation of patients recruited into our TREAT CASP study We anticipate that this model will be an advance on current methods that could ultimately be applied in clinical assessment of patients in the NHS once the validation is complete |
Type Of Material | Data analysis technique |
Provided To Others? | No |
Impact | Still in development |
Description | Chairman European Society of Cardiology Guideline on Hypertension 2018 |
Organisation | European Society of Cardiology (ESC) |
Country | France |
Sector | Charity/Non Profit |
PI Contribution | I am Chairman of this European clinical practice guideline in my speciality area of hypertension. This guideline typically is one of the most cited scientific publications in the world |
Collaborator Contribution | I chair a partnership of colleagues from all European countries in the writing and development of this guideline |
Impact | Will be published in August 2018 |
Start Year | 2017 |
Description | Clinical Lead for the National Early Warning Score (NEWS) |
Organisation | NHS England |
Country | United Kingdom |
Sector | Public |
PI Contribution | I led the development of the national early warning score (NEWS) on behalf of the Royal College of Physicians London in 2012. I led the update to the NEWS in 2017 (NEWS2) and championed its adoption by the NHS. NEWS2 is now endorsed by NHSE and NHSI as the national early warning score system for the NHS, the first country in the world to have a nationals system. I was also one of a small team who developed the educational programme on line which has been accessed by over 270,000 NHS staff for accreditation in the use of the NEWS |
Collaborator Contribution | Leadership and research underpinning the NEWS |
Impact | NEWS2 report, RCP London 2017 |
Start Year | 2017 |
Description | Clinical Lead for the National Early Warning Score (NEWS) |
Organisation | Royal College of Physicians of London |
Country | United Kingdom |
Sector | Learned Society |
PI Contribution | I led the development of the national early warning score (NEWS) on behalf of the Royal College of Physicians London in 2012. I led the update to the NEWS in 2017 (NEWS2) and championed its adoption by the NHS. NEWS2 is now endorsed by NHSE and NHSI as the national early warning score system for the NHS, the first country in the world to have a nationals system. I was also one of a small team who developed the educational programme on line which has been accessed by over 270,000 NHS staff for accreditation in the use of the NEWS |
Collaborator Contribution | Leadership and research underpinning the NEWS |
Impact | NEWS2 report, RCP London 2017 |
Start Year | 2017 |
Description | Clinical Practice Research Data link (CPRD) |
Organisation | Medicines and Healthcare Regulatory Agency |
Department | Clinical Practice Research Datalink (CPRD) |
Country | United Kingdom |
Sector | Public |
PI Contribution | Engaged with CPRD and obtained funding from NOCLOR to support CRPD assistance with recruitment |
Collaborator Contribution | Screening GP data bases to identify suitable patients to be invited to participate in this study and liaising with the GP practices to send out letter - 899 potential participants identified already |
Impact | 899 potential study participants being invited to participate in the study |
Start Year | 2013 |
Description | Collaboration with the UCL Farr institute |
Organisation | Farr Institute of Health Informatics Research |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Developing data science infrastructure strategy for the BRC renewal bid and to ensure closer collaboration with the NHS via UCLH This has also been instrumental in the success of our contribution to the NIHR Health Informatics Collaborative My contributions been leadership via the BRC and research and clinical expertise |
Collaborator Contribution | Major input on data science strategy and the development of our Health Informatics, Genomics, Omics and Data Science (HIGODS) cross cutting theme for our successful BRC application in 2016 which I led. Prof Harry Hemingway the UCL Farr Director is now the BRC HIGODS theme director which has led to even greater collaboration and working. For the TREAT CASP study we have used the UCL data safe haven embedded within the Farr institute The Farr institute has now become the lead site for the London centres for HDRUK - I am a co-applicant on the successful London Centres bid for HDRUK funding in 2018 |
Impact | There have been a number of publications emanating from the collaboration. The most significant output has been the establishment of a multidisciplinary research team embedded within the NHS to help drive data science at UCLH and via the NIHR HIC project |
Start Year | 2013 |
Description | Member of Board of Directors University College London Hospitals as Director of Research |
Organisation | University College Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | In my leadership role as Director of Research for UCLH, I was invited to join the Board in 2018 to ensure that the research hospital vision of UCLH is realised and supported at board level. This also ensures that research is considered a key function of UCLJH |
Collaborator Contribution | see above |
Impact | Numerous clinical research outputs from one of the most research active hospitals in the NHS |
Start Year | 2018 |
Description | Member of Board of Directors University College London Hospitals as Director of Research |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | In my leadership role as Director of Research for UCLH, I was invited to join the Board in 2018 to ensure that the research hospital vision of UCLH is realised and supported at board level. This also ensures that research is considered a key function of UCLJH |
Collaborator Contribution | see above |
Impact | Numerous clinical research outputs from one of the most research active hospitals in the NHS |
Start Year | 2018 |
Description | Member of global steering committee AMBER study |
Organisation | Relypsa, Inc. |
Country | United States |
Sector | Private |
PI Contribution | Design of a RCT evaluating the utility of a new potassium binding agent to facilitate the continued use of spironolactone for the treatment of resistant hypertension in patients with chronic kidney disease |
Collaborator Contribution | Design of study and oversight of RCTDeveloped links with NIHR network to engage UK sites in this global study |
Impact | RCT completed global recruitment in Nov 2018 and we are just analysing the data - likely high impact publication - target journal - the Lancet |
Start Year | 2017 |
Description | NIHR Wellcome UCL Hospitals CRF Director |
Organisation | National Institute for Health Research |
Department | UCLH/UCL Biomedical Research Centre |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | In June 2013 I assumed the role as Director of the NIHR Wellcome UCL Hospitals CRF. We have developed a collaboration with the Leonard Wolfson Experimental Neurology Centre (LWENS) to share expertise and develop joint SOPs and governance procedures for research I have led the development of a new CRF build for UCL Hospitals which was opened in 2016 and I then stepped down from the role as CRF Director to focus on my roles at NIHR UCLH/UCL BRC Director and Director of Research for UCLH I handed over the Directorship in 2017 to a newly appointed NIHR CRF Director I was co-applicant on successful bid for funding for the CRF from NIHR 2017-2022 £6.5m I continue to provide oversight of the BRC in my roles as BRC Director and UCLH Director of Research |
Collaborator Contribution | Developed the collaboration above to increase the depth and efficiency of our experimental medicine research. the BRC supports experimental medicine research in the NIHR UCLH CRF |
Impact | CRF redesignated a NIHR CRF in the 2016 national competition and was awarded £6.5m |
Start Year | 2013 |
Description | NIHR Wellcome UCL Hospitals CRF Director |
Organisation | University College Hospital |
Department | NIHR Comprehensive Biomedical Research Centre |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | In June 2013 I assumed the role as Director of the NIHR Wellcome UCL Hospitals CRF. We have developed a collaboration with the Leonard Wolfson Experimental Neurology Centre (LWENS) to share expertise and develop joint SOPs and governance procedures for research I have led the development of a new CRF build for UCL Hospitals which was opened in 2016 and I then stepped down from the role as CRF Director to focus on my roles at NIHR UCLH/UCL BRC Director and Director of Research for UCLH I handed over the Directorship in 2017 to a newly appointed NIHR CRF Director I was co-applicant on successful bid for funding for the CRF from NIHR 2017-2022 £6.5m I continue to provide oversight of the BRC in my roles as BRC Director and UCLH Director of Research |
Collaborator Contribution | Developed the collaboration above to increase the depth and efficiency of our experimental medicine research. the BRC supports experimental medicine research in the NIHR UCLH CRF |
Impact | CRF redesignated a NIHR CRF in the 2016 national competition and was awarded £6.5m |
Start Year | 2013 |
Description | NIHR Wellcome UCL Hospitals CRF Director |
Organisation | University College London |
Department | Leonard Wolfson Experimental Neurology Centre |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | In June 2013 I assumed the role as Director of the NIHR Wellcome UCL Hospitals CRF. We have developed a collaboration with the Leonard Wolfson Experimental Neurology Centre (LWENS) to share expertise and develop joint SOPs and governance procedures for research I have led the development of a new CRF build for UCL Hospitals which was opened in 2016 and I then stepped down from the role as CRF Director to focus on my roles at NIHR UCLH/UCL BRC Director and Director of Research for UCLH I handed over the Directorship in 2017 to a newly appointed NIHR CRF Director I was co-applicant on successful bid for funding for the CRF from NIHR 2017-2022 £6.5m I continue to provide oversight of the BRC in my roles as BRC Director and UCLH Director of Research |
Collaborator Contribution | Developed the collaboration above to increase the depth and efficiency of our experimental medicine research. the BRC supports experimental medicine research in the NIHR UCLH CRF |
Impact | CRF redesignated a NIHR CRF in the 2016 national competition and was awarded £6.5m |
Start Year | 2013 |
Description | Steering Committee Member NIRVARNA studies of a new neprilysin inhibitor in resistant hypertension |
Organisation | Novartis |
Country | Global |
Sector | Private |
PI Contribution | Novartis |
Collaborator Contribution | Design of new global RCT evaluating a new NEP-inhibitor in resistant hypertension This drug development program was terminated by Novartis in 2019 |
Impact | None yet |
Start Year | 2017 |
Title | methods to measure aortic pressure |
Description | devices currently marketed. we have developed a partnership between UCL Business and Healthstats UK |
Type | Diagnostic Tool - Non-Imaging |
Current Stage Of Development | Market authorisation |
Year Development Stage Completed | 2011 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | I won the Times Higher Award for outstanding contribution to innovation and technology 2011 URL:http://www2.le.ac.uk/offices/press/press-releases/2011/november/university-of-leicester-wins-national-award-for-outstanding-contribution-to-innovation-and-technology-1 |
URL | https://clinicaltrials.gov/show/NCT00819767 |
Description | Attended House of Lords Select Committee to answer questions on the life science strategy |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Policymakers/politicians |
Results and Impact | I was invited to give evidence to a house of lords select committee on the government side sciences strategy in my capacity as a BRC Director |
Year(s) Of Engagement Activity | 2018 |
URL | http://goo.gl/edE5ik |
Description | BBC News |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | major story on BBC news about our research - see link below many enquiries from the public which i have replied to the technology we have developed and cited in this report on BBC is now being used in patient assessment in the NHS and in our research see above also had enquiries from Apple and Samsung about business collaboration related to this technology |
Year(s) Of Engagement Activity | 2013 |
URL | http://www.bbc.co.uk/news/health-22812477 |
Description | Development of the UCL Hospitals Research Gateway |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | An online gateway highlighting the research opportunities for members of the general public linked to their disease of interest Mutliple website hits and enquiries about participation in studies from the general public who had never previously engaged with research |
Year(s) Of Engagement Activity | 2014 |
URL | http://www.uclhospitals.brc.nihr.ac.uk/news/uclh-research-gateway-launches |
Description | Meeting at Foreign office to discuss sector bid for life sciences for government economic strategy |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | contribution to discussions to frame the sector bid for life sciences led by Sir John Bell |
Year(s) Of Engagement Activity | 2017 |
Description | NIHR UCL Hospitals BRC Newsletter |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | Local |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | As BRC Director I Developed a BRC newsletter for communication to the UCL and UCLH community about the work of the BRC wider and better engagement with the BRC |
Year(s) Of Engagement Activity | 2012,2013 |
URL | http://www.uclhospitals.brc.nihr.ac.uk |
Description | New Method to Measure Aortic Pressure - BBC TV |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Type Of Presentation | Paper Presentation |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | reported a new method to estimate aortic pressure - could revolutionise future BP measurement received major BBC news coverage major BBC new coverage |
Year(s) Of Engagement Activity | 2011 |
URL | http://www.bbc.co.uk/news/health-12518633 |
Description | Presentation on London BRCs and their contribution to economic growth at Med City event in London February 2017 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | major show and tell event with industry (SMEs and major industry) highlighted collaborative opportunities in biomedical science with London and Oxford and Cambridge BRCs |
Year(s) Of Engagement Activity | 2017 |
Description | Schools visit to review BRC strategy |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | BRC Director and theme leads presented the BRC strategy and objectives to school science students for discussion and debate - excellent feedback from the students |
Year(s) Of Engagement Activity | 2016 |
Description | UCL Hospitals Research Open day for the general public |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Excellent feedback from the general public and schools who attended and major interest in participation in our research project - led to increased recruitment A number of schools asking if they could attend next year |
Year(s) Of Engagement Activity | 2014 |
Description | UCL Hospitals Research open day June 2016 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Major research open day organised by our BRC and hosted by UCLH. Over 50 stalls displaying ongoing clinical and transitional research |
Year(s) Of Engagement Activity | 2016 |